CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease
Henry Ford Health System
100 participants
May 10, 2023
OBSERVATIONAL
Conditions
Summary
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Eligibility
Inclusion Criteria1
- Patients >18 year old admitted for allo SCT PB for malignant disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05718791